Table 1.
Definitions of AP CML
The WHO, ELN, and MD Anderson Cancer Center definitions of AP CML are shown. The WHO AP criteria also include the following: persistent thrombocytosis (> 1000 × 109/L) or leukocytosis (> 10 × 109/L) or spleen size unresponsive to therapy. Basophils or blasts may be measured in peripheral blood or BM. The MD Anderson and ELN definitions have been used extensively to define CP versus AP CML in clinical trials.
